Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to ...
13:38 EDT 30 Jun 2012 | LaMerie
- The phase II interferon-free combination study with TMC435 and daclatasvir will evaluate treatment-naïve or previous null responder patients with HCV genotype 1a and 1b
- The study will include approx. 180 patients and will evaluate a combination of TMC435 and daclatasvir, with or without Ribavirin, in four different cohorts for 12 or 24 weeks of treatment
Original Article: Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to ...
More From BioPortfolio on "Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
